Dr. Christine Allen, Co-Founder and CEO of Intrepid Labs, and Dr. Andrew Lewis, Chief Scientific Officer of Quotient Sciences, explain how AI can be used in drug development to shorten development timelines.
Christine Allen
Advertisement
Dr. Christine Allen is co-founder and CEO of Intrepid Labs. Dr. Allen is an internationally recognized expert in drug formulation and development, with over 200 peer-reviewed publications. She is a Professor at the University of Toronto and a Fellow of both the American Institute for Medical and Biological Engineering and the Canadian Academy of Health Sciences. She has held numerous leadership roles across academia and industry, including President of the Controlled Release Society and Editor-in-Chief of the Journal of Controlled Release.
Articles by Christine Allen
Dr. Christine Allen, Co-Founder and CEO of Intrepid Labs, and Dr. Andrew Lewis, Chief Scientific Officer of Quotient Sciences, explain how AI can be used in drug development to shorten development timelines.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Duloxetine Recall Highlights Generic Manufacturing Quality Gaps
2
Is Compliant AI in Pharma Even Possible? The Search for an Honest Answer
3
A Lifecycle Approach to Peptide Formulation in Prefilled Syringes for High-Speed Autoinjector Assembly
4
Reimagining Signal Management: How Autonomous Pharmacovigilance Could Render Reporting Timelines a Thing of the Past
5